OSD Overhaul Three new pipeline therapies may offer relief to patients with ocular surface disease Roisin McGuigan, Mark Hillen | 01/15/2016











It’s estimated that there are nearly 100 million people worldwide who have some form of dry eye disease (DED). However, most people with DED go undiagnosed, and for those who do receive a diagnosis, the most commonly offered treatment is artificial tears. This might be about to change. We review three of the latest developments in the DED therapy pipeline.

Read the full article now Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be! Login Email Password Forgot your password? Keep me logged in Log in Or register now - it’s free and always will be! You will benefit from: Unlimited access to ALL articles

News, interviews & opinions from leading industry experts

Receive print (and PDF) copies of The Ophthalmologist magazine Register Or Login via Social Media Twitter By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Authors

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a deputy editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.